The Advanced Medical Technology Association (AdvaMed) today bestowed the second annual AdvaMed Lifetime Achievement Award to Medtronic co-founder Earl Elmer Bakken, creator of the first wearable, battery-operated external pacemaker.
A new study by the Analysis Group shows that private insurers are rapidly adopting new provider payment models – including pay-for-performance and financial risk-sharing arrangements – and tightening coverage evidence requirements for new technologies.
“AdvaMed supports appropriate disclosure of relationships between medical technology companies and physicians."
“AdvaMedDx appreciates FDA’s release of draft guidance on a risk-based approach to the regulation of LDTs and looks forward to reviewing and providing comments. LDTs are increasingly being used to diagnose and guide the treatment of potentially life-threatening conditions.
“Repealing this tax will help ensure the U.S. maintains its global leadership in this high-tech manufacturing sector and advance the development of new cures and treatments,” said Stephen J. Ubl, President and CEO of AdvaMed.
“AdvaMed commends the call from APEC’s Small and Medium Enterprise (SME) ministers to double the number of codes of ethics in the region for the medical device and biopharmaceutical sectors by 2015.
Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued a statement on the release of an omnibus jobs bill (H.R. 4) in the U.S. House of Representatives which includes language to repeal the medical device excise tax.
In the written testimony provided to the committee, Fish said, “For years, stakeholders have recognized the inadequacy of current oversight of LDTs and called for FDA to enforce existing regulations that apply to LDTs just as they do to all other diagnostics.”
“We are pleased Rep. Maffei helped lead our discussion on the importance of supporting medical technology companies at the federal level,”
“AdvaMedDx’s membership supports a modernized and flexible approach to the review process for diagnostics. Such a review process should create a reasonable pathway to market and advance patient care by promoting timely access to innovative technologies."